Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

被引:6
|
作者
Zeng, Li [1 ]
Ma, Gang [2 ,3 ]
Chen, Kai [1 ]
Zhou, Qiao [3 ,4 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Neurol, Chengdu, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immune checkpoint inhibitor; rheumatic immune-related adverse event; bibliometric; research trends; VOSviewer; CiteSpace; INDUCED SARCOIDOSIS; TUMOR RESPONSE; IMMUNOTHERAPY; AUTOIMMUNITY; NIVOLUMAB; BLOCKADE; ANTIBODY; CTLA4;
D O I
10.3389/fimmu.2023.1242336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods.Methods The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined.Results In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to "monoclonal antibody," "anti-CLTA4 antibody," and "melanoma". This was followed by a rise in interest related to "sarcoidosis," "safety," "inflammatory arthritis," and "preexisting autoimmune."Conclusion This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Rheumatic immune-related adverse events induced by immune checkpoint inhibitors
    Zhong, Hui
    Zhou, Jiaxin
    Xu, Dong
    Zeng, Xiaofeng
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (03) : 178 - 185
  • [2] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Day, Daphne
    Hansen, Aaron R.
    BIODRUGS, 2016, 30 (06) : 571 - 584
  • [3] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Daphne Day
    Aaron R. Hansen
    BioDrugs, 2016, 30 : 571 - 584
  • [4] Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)
    Tingry, Thomas
    Massy, Emmanuel
    Piperno, Muriel
    Auroux, Maxime
    Kostine, Marie
    Maillet, Denis
    Amini-Adle, Mona
    Fabien, Nicole
    Estublier, Charline
    Goncalves, David
    Girard, Nicolas
    Confavreux, Cyrille B.
    BULLETIN DU CANCER, 2021, 108 (06) : 643 - 653
  • [5] Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
    Xiao, Yan
    Zeng, Lin
    Shen, Qinglin
    Zhou, Zhiyong
    Mao, Zhifang
    Wang, Qin
    Zhang, Xiquan
    Li, Yingliang
    Yao, Weirong
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [6] Advances on immune-related adverse events associated with immune checkpoint inhibitors
    Yong Fan
    Yan Geng
    Lin Shen
    Zhuoli Zhang
    Frontiers of Medicine, 2021, 15 : 33 - 42
  • [7] Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
    Gan, Linyang
    Chen, Huan
    Liu, Xiaowei
    Zhang, Li
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Advances on immune-related adverse events associated with immune checkpoint inhibitors
    Yong Fan
    Yan Geng
    Lin Shen
    Zhuoli Zhang
    Frontiers of Medicine, 2021, 15 (01) : 33 - 42
  • [9] Advances on immune-related adverse events associated with immune checkpoint inhibitors
    Fan, Yong
    Geng, Yan
    Shen, Lin
    Zhang, Zhuoli
    FRONTIERS OF MEDICINE, 2021, 15 (01) : 33 - 42
  • [10] Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
    Jo, Wonyoung
    Won, Taejoon
    Daoud, Abdel
    Cihakova, Daniela
    FRONTIERS IN IMMUNOLOGY, 2024, 15